Dried blood spots for HIV-1 drug resistance genotyping in decentralized settings in Senegal

Journal of Medical Virology

Volumn 86, Issue 1, 2014, Pages 45-51

  Diouara, Abou Abdallah Malick ^a   Diop Ndiaye, Halimatou ^a   Kebe Fall, Khady ^a   Tchiakpè, Edmond ^a   Ndiaye, Ousseynou ^a   Ayouba, Ahidjo ^b   Peeters, Martine ^b   Mboup, Souleymane ^a   Kane, Coumba Toure ^a  

^a UNIVERSITÉ CHEIKH ANTA DIOP   (Senegal)

^b INSTITUT DE RECHERCHE POUR LE DÉVELOPPEMENT   (France)

Author keywords

Dried blood spots; Drug resistance; HIV 1; Senegal

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS ZIDOVUDINE; NUCLEIC ACID;

ADULT; AGED; ARTICLE; DATA BASE; DRIED BLOOD SPOT TESTING; EXTRACTION; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY; MAJOR CLINICAL STUDY; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PHYLOGENY; ROOM TEMPERATURE; SENEGAL; STRUCTURAL GENE; TREATMENT DURATION; TREATMENT FAILURE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

DRIED BLOOD SPOTS; DRUG RESISTANCE; HIV-1; SENEGAL;

ADOLESCENT; AGED; ANTI-HIV AGENTS; BLOOD; DESICCATION; DRUG MONITORING; FEMALE; GENOTYPE; GENOTYPING TECHNIQUES; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; SENEGAL; SPECIMEN HANDLING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84887818305     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23778     Document Type: Article

References (32)

1. Aghokeng A, Monleau M, Dagnra A, Kania D, Ngo-Giang-Huong N, Touré-Kane C, Truong L, Chaix ML, Peeters M, Ayouba A. and ANRS 12186 Study Group. 2011. Virological outcome and frequency of drug resistance mutations in HIV-1+ patients receiving first-line ARV regimen and monitored with the clinical approach in Southeast Asia and Sub-Saharan Africa. 19th Conference on retroviruses and opportunistic infections: Abstract N° 737, Session 125-Poster Abstracts.
2. Bertagnolio S, Soto-Ramirez L, Pilon R, Rodriguez R, Viveros M, Fuentes L, Harrigan PR, Mo T, Sutherland D, Sandstrom P. 2007. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 12:107-113.
3. Charpentier C, Gody JC, Tisserand P, Matta M, Fournier J, Mbitikon O, Belec L. 2011. Usefulness of a genotypic resistance test using dried blood spot specimens in African HIV-infected children with virological failure according to the 2010-revised WHO criteria. Arch Virol 156:1603-1606.
4. CNLS-Sénégal, 2012. Rapport de situation sur la riposte nationale à l'épidémie de VIH/SIDA Sénégal: 2010-2011. 1-94. Available from: http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_SN_Narrative_Report%5B2011%5D.pdf [Accessed May 16, 2013].
5. Dagnra AY, Vidal N, Mensah A, Patassi A, Aho K, Salou M, Monleau M, Prince-David M, Singo A, Pitche P, Delaporte E, Peeters M. 2011. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lome, Togo. J Int AIDS Soc 14:30.
6. De Beaudrap P, Thiam M, Diouf A, Toure-Kane C, Ngom-Gueye NF, Vidal N, Mboup S, Ndoye I, Sow PS, Delaporte E. for the Asg. 2013. Risk of virological failure and drug resistance during first and second-line antiretroviral therapy in a 10-year cohort in Senegal: Results from the ANRS 1215 cohort. J Acquir Immune Defic Syndr 62:381-387.
7. Diop-Ndiaye H, Toure-Kane C, Leye N, Ngom-Gueye NF, Montavon C, Peeters M, Mboup S. 2010. Antiretroviral drug resistance mutations in antiretroviral-naive patients from Senegal. AIDS Res Hum Retroviruses 26:1133-1138.
8. Diouara AAM, Sow A, Leye N, Diop-Ndiaye H, Ndiaye O, Monleau M, Ayouba A, Aghokeng A, Kébé K, Thiam M, Bangoura N, Gueye SB, Diakhate R, Peeters M, Toure-Kane NC, Mboup S. 2012. Comparaison des charges virales et des mutations de résistance entre plasma et DBS au Sénégal. Abstract Book: 6éme Conférence Francophone VIH/SIDA, 25-28 Mars - Genève Suisse abstract numéro 82.
9. Edgar RC. 2004. MUSCLE: Multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res 32:1792-1797.
10. Gouy M, Guindon S, Gascuel O. 2010. SeaView version 4: A multiplatform graphical user interface for sequence alignment and phylogenetic tree building. Mol Biol Evol 27:221-224.
11. Guthrie R, Susi A. 1963. A Simple phenylalanine method for detecting phenylketonuria in large populations of newborn infants. Pediatrics 32:338-343.
12. Hannon WH, Lewis DS, Jones WK, Powell MK. 1989. A quality assurance program for human immunodeficiency virus seropositivity screening of dried-blood spot specimens. Infect Control Hosp Epidemiol 10:8-13.
13. Hanson DL, Adje-Toure C, Talla-Nzussouo N, Eby P, Borget MY, Kouadio LY, Celestin BE, Tossou O, Eholie S, Kadio A, Chorba T, Nkengasong JN. 2009. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 25:489-495.
14. Inzaule S, Yang C, Kasembeli A, Nafisa L, Okonji J, Oyaro B, Lando R, Mills LA, Laserson K, Thomas T, Nkengasong J, Zeh C. 2013. Field evaluation of a broadly sensitive HIV-1 in-house genotyping assay for use with both plasma and dried blood spot specimens in a resource-limited country. J Clin Microbiol 51:529-539.
15. Kane CT, Ndiaye HD, Diallo S, Ndiaye I, Wade AS, Diaw PA, Gaye-Diallo A, Mboup S. 2008. Quantitation of HIV-1 RNA in dried blood spots by the real-time NucliSENS EasyQ HIV-1 assay in Senegal. J Virol Methods 148:291-295.
16. Kantor R, Diero L, Delong A, Kamle L, Muyonga S, Mambo F, Walumbe E, Emonyi W, Chan P, Carter EJ, Hogan J, Buziba N. 2009. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 49:454-462.
17. Kebe K, Ndiaye O, Ndiaye HD, Mengue PM, Guindo PM, Diallo S, Leye N, Gueye SB, Diallo AG, Kane CT, Mboup S. 2011. RNA versus DNA (NucliSENS EasyQ HIV-1 v1.2 versus Amplicor HIV-1 DNA test v1.5) for early diagnosis of HIV-1 infection in infants in Senegal. J Clin Microbiol 49:2590-2593.
18. Kebe K, Thiam M, Diagne Gueye NR, Diop H, Dia A, Signate Sy H, Charpentier C, Belec L, Mboup S, Toure Kane C. 2013. High rate of antiretroviral drug resistance mutations in HIV type 1-infected Senegalese children in virological failure on first-line treatment according to the World Health Organization guidelines. AIDS Res Hum Retroviruses 29:242-249.
19. Laurent C, Diakhate N, Gueye NF, Toure MA, Sow PS, Faye MA, Gueye M, Laniece I, Toure Kane C, Liegeois F, Vergne L, Mboup S, Badiane S, Ndoye I, Delaporte E. 2002. The Senegalese government's highly active antiretroviral therapy initiative: An 18-month follow-up study. AIDS 16:1363-1370.
20. Leelawiwat W, Young NL, Chaowanachan T, Ou CY, Culnane M, Vanprapa N, Waranawat N, Wasinrapee P, Mock PA, Tappero J, McNicholl JM. 2009. Dried blood spots for the diagnosis and quantitation of HIV-1: Stability studies and evaluation of sensitivity and specificity for the diagnosis of infant HIV-1 infection in Thailand. J Virol Methods 155:109-117.
21. McNulty A, Jennings C, Bennett D, Fitzgibbon J, Bremer JW, Ussery M, Kalish ML, Heneine W, Garcia-Lerma JG. 2007. Evaluation of dried blood spots for human immunodeficiency virus type 1 drug resistance testing. J Clin Microbiol 45:517-521.
22. Monleau M, Faihun F, Affolabi D, Afangnihoun A, Boillot F, Anagonou S, Peeters M, Delaporte E. 2011. Antiretroviral drug resistance in HIV-1 infected patients receiving antiretroviral treatment in routine clinics in Cotonou, Benin. J AIDS HIV Res 3:114-120.
23. Rottinghaus EK, Ugbena R, Diallo K, Bassey O, Azeez A, Devos J, Zhang G, Aberle-Grasse J, Nkengasong J, Yang C. 2012. Dried blood spot specimens are a suitable alternative sample type for HIV-1 viral load measurement and drug resistance genotyping in patients receiving first-line antiretroviral therapy. Clin Infect Dis 54:1187-1195.
24. Sangsari S, Milloy MJ, Ibrahim A, Kerr T, Zhang R, Montaner J, Wood E. 2012. Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: An observational study. BMC Infect Dis 12:22.
25. Sungkanuparph S, Win MM, Kiertiburanakul S, Phonrat B, Maek-a-nantawat W. 2012. HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting. Int J STD AIDS 23:316-318.
26. Thiam M, Diop-Ndiaye H, Diouf AD, Vidal N, Ndiaye O, Ndiaye I, Ngom-Gueye NF, Diallo S, Diongue OD, Camara M, Seck A, Mboup S, Toure-Kane C. 2013. HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. J Clin Microbiol 51:578-584.
27. Toure-Kane C, Montavon C, Faye MA, Gueye PM, Sow PS, Ndoye I, Gaye-Diallo A, Delaporte E, Peeters M, Mboup S. 2000. Identification of all HIV type 1 group M subtypes in Senegal, a country with low and stable seroprevalence. AIDS Res Hum Retroviruses 16:603-609.
28. UNAIDS. 2012. UNAIDS report on the global AIDS epidemic 2012. pp 1-212 [UNAIDS Global AIDS Report web site]. Available from: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012JC2434_WorldAIDSday_results_en.pdf [Accessed May 16, 2013].
29. van Deursen P, Oosterlaken T, Andre P, Verhoeven A, Bertens L, Trabaud MA, Ligeon V, de Jong J. 2010. Measuring human immunodeficiency virus type 1 RNA loads in dried blood spot specimens using NucliSENS EasyQ HIV-1 v2.0. J Clin Virol 47:120-1125.
30. WHO. 2006. Antiretroviral therapy for hiv infection in adults and adolescents: Recommendations for a public health approach. Switzerland: WHO Press, pp 1-134.
31. WHO. 2010. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach: 2010 Revision. Available from: http://www.ncbi.nlm.nih.gov/books/NBK138540/pdf/TOC.pdf [Accessed May 16, 2013].
32. WHO. 2012. WHO manual for HIV drug resistance testing using dried blood spot specimens. Available from: http://apps.who.int/iris/bitstream/10665/75829/10661/WHO_HIV_12012.10630_eng.pdf [Accessed May 16, 2013].